Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 May 21;13(6):1760.
doi: 10.3390/nu13061760.

Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study

Juan F Alcala-Diaz  1   2 , Laura Limia-Perez  1 , Ricardo Gomez-Huelgas  3   4 , Maria D Martin-Escalante  5 , Begoña Cortes-Rodriguez  6 , Jose L Zambrana-Garcia  7 , Marta Entrenas-Castillo  8 , Ana I Perez-Caballero  1   2 , Maria D López-Carmona  3   4 , Javier Garcia-Alegria  5   9 , Aquiles Lozano Rodríguez-Mancheño  6 , Maria Del Sol Arenas-de Larriva  8 , Luis M Pérez-Belmonte  3   4 , Irwin Jungreis  10   11 , Roger Bouillon  12 , Jose Manual Quesada-Gomez  13 , Jose Lopez-Miranda  1   2
Affiliations
Clinical Trial

Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study

Juan F Alcala-Diaz et al. Nutrients. .

Abstract

Context: Calcifediol has been proposed as a potential treatment for COVID-19 patients.

Objective: To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19.

Design: Retrospective, multicenter, open, non-randomized cohort study.

Settings: Hospitalized care.

Patients: Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain.

Intervention: Patients received calcifediol (25-hydroxyvitamin D3) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not.

Main outcome measure: In-hospital mortality during the first 30 days after admission.

Results: A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; p < 0.01). Patients who received calcifediol after admission were more likely than those not receiving treatment to have comorbidity and a lower rate of CURB-65 score for pneumonia severity ≥ 3 (one point for each of confusion, urea > 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure < 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg, and age ≥ 65 years), acute respiratory distress syndrome (moderate or severe), c-reactive protein, chronic kidney disease, and blood urea nitrogen. In a multivariable logistic regression model, adjusting for confounders, there were significant differences in mortality for patients receiving calcifediol compared with patients not receiving it (OR = 0.16 (95% CI 0.03 to 0.80).

Conclusion: Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings.

Keywords: COVID-19; COVID-19 drug treatment; SARS-CoV-2; calcifediol; vitamin D.

PubMed Disclaimer

Conflict of interest statement

JFAD received lecture fees from Bayer, Grunenthal Pharma, Esteve, Ferrer, and Boehringer Ingelheim outside the submitted work. LLP received lecture fees from Gebro Pharma S.A., Boehringer Ingelheim, Pfizer, Mylan, Almirall, SANOFI, and ESTEVE outside the submitted work. IJ, RGH, MDME, BCR, JLZG, MEC, AIPC, MDLC, JGA, ALRM, MDSAL, and LMPB have nothing to declare. RB received lecture fees from Abiogen, Faes Farma, Fresenius, and Proctor and Gamble outside the submitted work. JMQG received lecture fees from FAES Farma (Spain) and Amgen related to vitamin D—these activities in no way influenced the writing of the present manuscript. JLM received lecture fees from AMGEN, SANOFI, FERRER, Laboratorios Dr. Esteve, and Boehringer Ingelheim-Lilly outside the submitted work. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Flow chart of patients included in the study. Center A, Hospital Universitario Reina Sofia (Córdoba, Spain); Center B, Hospital Costa del Sol (Marbella, Spain); Center C, Hospital Alto Gualdalquivir (Andújar, Spain); Center D, Hospital Montilla (Córdoba, Spain); Center E, Hospital Universitario Regional (Málaga, Spain).
Figure 2
Figure 2
Cumulative distribution of patients presenting in-hospital death according to treatment groups.
See this image and copyright information in PMC

References

    1. Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324:782–793. doi: 10.1001/jama.2020.12839. - DOI - PubMed
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. COVID-19 Coronavirus Pandemic. [(accessed on 18 April 2021)]; Available online: https://www.worldometers.info/coronavirus/?
    1. Arunachalam P.S., Wimmers F., Mok C.K.P., Perera R., Scott M., Hagan T., Sigal N., Feng Y., Bristow L., Tak-Yin Tsang O., et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369:1210–1220. doi: 10.1126/science.abc6261. - DOI - PMC - PubMed
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7. - DOI - PMC - PubMed